

# Roman Hovorka

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8570422/publications.pdf>

Version: 2024-02-01

312  
papers

17,979  
citations

18482  
62  
h-index

16650  
123  
g-index

322  
all docs

322  
docs citations

322  
times ranked

8496  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
2	International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640.	8.6	1,376
3	Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. Physiological Measurement, 2004, 25, 905-920.	2.1	1,025
4	Intensive insulin therapy: enhanced Model Predictive Control algorithm versus standard care. Intensive Care Medicine, 2009, 35, 123-128.	8.2	525
5	Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet, The, 2010, 375, 743-751.	13.7	429
6	Home Use of an Artificial Beta Cell in Type 1 Diabetes. New England Journal of Medicine, 2015, 373, 2129-2140.	27.0	397
7	Continuous glucose monitoring and closed-loop systems. Diabetic Medicine, 2006, 23, 1-12.	2.3	371
8	Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet, The, 2018, 392, 1321-1329.	13.7	302
9	Partitioning glucose distribution/transport, disposal, and endogenous production during IVGTT. American Journal of Physiology - Endocrinology and Metabolism, 2002, 282, E992-E1007.	3.5	297
10	Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis. BMJ: British Medical Journal, 2018, 361, k1310.	2.3	294
11	Closed-loop insulin delivery: from bench to clinical practice. Nature Reviews Endocrinology, 2011, 7, 385-395.	9.6	274
12	Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ: British Medical Journal, 2011, 342, d1855-d1855.	2.3	217
13	Insulin Kinetics in Type-1 Diabetes: Continuous and Bolus Delivery of Rapid Acting Insulin. IEEE Transactions on Biomedical Engineering, 2005, 52, 3-12.	4.2	209
14	Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes. New England Journal of Medicine, 2016, 375, 644-654.	27.0	203
15	Simulation Environment to Evaluate Closed-Loop Insulin Delivery Systems in Type 1 Diabetes. Journal of Diabetes Science and Technology, 2010, 4, 132-144.	2.2	195
16	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179.	8.6	195
17	Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. Diabetes Care, 2014, 37, 1204-1211.	8.6	193
18	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients. Diabetes Care, 2006, 29, 271-276.	8.6	189

#	ARTICLE	IF	CITATIONS
19	Coming of age: the artificial pancreas for type 1 diabetes. <i>Diabetologia</i> , 2016, 59, 1795-1805.	6.3	187
20	Clinical review: Consensus recommendations on measurement of blood glucose and reporting glycemic control in critically ill adults. <i>Critical Care</i> , 2013, 17, 229.	5.8	169
21	ISEC: a program to calculate insulin secretion. <i>Computer Methods and Programs in Biomedicine</i> , 1996, 50, 253-264.	4.7	150
22	New closed-loop insulin systems. <i>Diabetologia</i> , 2021, 64, 1007-1015.	6.3	146
23	Closed-Loop Basal Insulin Delivery Over 36 Hours in Adolescents With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 838-844.	8.6	144
24	Closed-Loop Insulin Delivery for Glycemic Control in Noncritical Care. <i>New England Journal of Medicine</i> , 2018, 379, 547-556.	27.0	144
25	Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 701-709.	11.4	140
26	Closing the loop overnight at home setting: psychosocial impact for adolescents with type 1 diabetes and their parents. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000025.	2.8	132
27	Closing the Loop: The Adicol Experience. <i>Diabetes Technology and Therapeutics</i> , 2004, 6, 307-318.	4.4	131
28	Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 261-270.	11.4	120
29	Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 406-411.	8.6	115
30	Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 21-39.	4.0	115
31	Day and Night Home Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes: Three-Center Randomized Crossover Study. <i>Diabetes Care</i> , 2014, 37, 1931-1937.	8.6	113
32	Day-and-Night Closed-Loop Insulin Delivery in a Broad Population of Pregnant Women With Type 1 Diabetes: A Randomized Controlled Crossover Trial. <i>Diabetes Care</i> , 2018, 41, 1391-1399.	8.6	113
33	A probabilistic approach to glucose prediction and insulin dose adjustment: description of metabolic model and pilot evaluation study. <i>Computer Methods and Programs in Biomedicine</i> , 1994, 41, 153-165.	4.7	112
34	Day-and-Night Hybrid Closed-Loop Insulin Delivery in Adolescents With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial. <i>Diabetes Care</i> , 2016, 39, 1168-1174.	8.6	105
35	Technology in the management of type 1 diabetes mellitus – current status and future prospects. <i>Nature Reviews Endocrinology</i> , 2018, 14, 464-475.	9.6	103
36	Patients' and caregivers' experiences of using continuous glucose monitoring to support diabetes self-management: qualitative study. <i>BMC Endocrine Disorders</i> , 2018, 18, 12.	2.2	102

#	ARTICLE	IF	CITATIONS
37	Safety and Efficacy of 24-h Closed-Loop Insulin Delivery in Well-Controlled Pregnant Women With Type 1 Diabetes. <i>Diabetes Care</i> , 2011, 34, 2527-2529.	8.6	101
38	Glycemic Variability Correlates Strongly With Postprandial $\beta$ -Cell Dysfunction in a Segment of Type 2 Diabetic Patients Using Oral Hypoglycemic Agents. <i>Diabetes Care</i> , 2009, 32, 1058-1062.	8.6	99
39	Closing the Loop in Adults, Children and Adolescents With Suboptimally Controlled Type 1 Diabetes Under Free Living Conditions: A Psychosocial Substudy. <i>Journal of Diabetes Science and Technology</i> , 2017, 11, 1080-1088.	2.2	99
40	Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes. <i>New England Journal of Medicine</i> , 2022, 386, 209-219.	27.0	99
41	Blood Glucose Control by a Model Predictive Control Algorithm with Variable Sampling Rate Versus a Routine Glucose Management Protocol in Cardiac Surgery Patients: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 2960-2964.	3.6	98
42	Day and Night Closed-Loop Control in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 3882-3887.	8.6	95
43	Feasibility of fully automated closed-loop glucose control using continuous subcutaneous glucose measurements in critical illness: a randomized controlled trial. <i>Critical Care</i> , 2013, 17, R159.	5.8	94
44	Psychosocial aspects of closed- and open-loop insulin delivery: closing the loop in adults with Type 1 diabetes in the home setting. <i>Diabetic Medicine</i> , 2015, 32, 601-608.	2.3	91
45	Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-group trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 117-124.	11.4	91
46	Comparison of Three Protocols for Tight Glycemic Control in Cardiac Surgery Patients. <i>Diabetes Care</i> , 2009, 32, 757-761.	8.6	90
47	Tight glycaemic control by an automated algorithm with time-variant sampling in medical ICU patients. <i>Intensive Care Medicine</i> , 2008, 34, 1224-1230.	8.2	87
48	A simulation model of glucose regulation in the critically ill. <i>Physiological Measurement</i> , 2008, 29, 959-978.	2.1	86
49	Pathophysiology of postprandial hyperglycaemia in women with type 1 diabetes during pregnancy. <i>Diabetologia</i> , 2012, 55, 282-293.	6.3	85
50	Quantifying the Acute Changes in Glucose with Exercise in Type 1 Diabetes: A Systematic Review and Meta-Analysis. <i>Sports Medicine</i> , 2015, 45, 587-599.	6.5	83
51	Closed-loop insulin delivery for treatment of type 1 diabetes. <i>BMC Medicine</i> , 2011, 9, 120.	5.5	82
52	Effects of Intravenous Infusion of Lipid-Free Apo A-I in Humans. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1996, 16, 1203-1214.	2.4	80
53	Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Very Young Children: A Multicenter, 3-Week, Randomized Trial. <i>Diabetes Care</i> , 2019, 42, 594-600.	8.6	79
54	Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 1035-1064.	2.2	77

#	ARTICLE	IF	CITATIONS
55	Pancreatic Î²-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 744-750.	3.6	73
56	Reduced burden of diabetes and improved quality of life: Experiences from unrestricted day&night hybrid closed-loop use in very young children with type 1 diabetes. Pediatric Diabetes, 2019, 20, 794-799.	2.9	72
57	Is an artificial pancreas (closed-loop system) for Type 1 diabetes effective?. Diabetic Medicine, 2019, 36, 279-286.	2.3	72
58	The Future of Continuous Glucose Monitoring: Closed Loop. Current Diabetes Reviews, 2008, 4, 269-279.	1.3	69
59	A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings. Journal of Diabetes Science and Technology, 2023, 17, 1226-1242.	2.2	69
60	Continuous glucose control in the ICU: report of a 2013 round table meeting. Critical Care, 2014, 18, 226.	5.8	68
61	Perioperative Tight Glucose Control Reduces Postoperative Adverse Events in Nondiabetic Cardiac Surgery Patients. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3081-3089.	3.6	67
62	How to measure insulin secretion. Diabetes/metabolism Reviews, 1994, 10, 91-117.	0.3	66
63	Home Use of Day-and-Night Hybrid Closed-Loop Insulin Delivery in Suboptimally Controlled Adolescents With Type 1 Diabetes: A 3-Week, Free-Living, Randomized Crossover Trial. Diabetes Care, 2016, 39, 2019-2025.	8.6	65
64	Closed-Loop Insulin Delivery in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 2012, 41, 105-117.	3.2	64
65	Glucose Control in the ICU. Journal of Diabetes Science and Technology, 2016, 10, 1372-1381.	2.2	64
66	Fully closed-loop insulin delivery in inpatients receiving nutritional support: a two-centre, open-label, randomised controlled trial. Lancet Diabetes and Endocrinology, the, 2019, 7, 368-377.	11.4	59
67	Pancreatic Î²-Cell Responsiveness during Meal Tolerance Test: Model Assessment in Normal Subjects and Subjects with Newly Diagnosed Noninsulin-Dependent Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 1998, 83, 744-750.	3.6	59
68	Overnight Closed-Loop Insulin Delivery with Model Predictive Control: Assessment of Hypoglycemia and Hyperglycemia Risk Using Simulation Studies. Journal of Diabetes Science and Technology, 2009, 3, 1109-1120.	2.2	58
69	Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. Diabetes, Obesity and Metabolism, 2021, 23, 1389-1396.	4.4	58
70	A comparison of six deconvolution techniques. Journal of Pharmacokinetics and Pharmacodynamics, 1996, 24, 283-299.	0.6	55
71	Attainment of Metabolic Goals in the Integrated UK Islet Transplant Program With Locally Isolated and Transported Preparations. American Journal of Transplantation, 2013, 13, 3236-3243.	4.7	55
72	Evaluation of glucose controllers in virtual environment: methodology and sample application. Artificial Intelligence in Medicine, 2004, 32, 171-181.	6.5	54

#	ARTICLE	IF	CITATIONS
73	Measuring prehepatic insulin secretion using a population model of C-peptide kinetics: accuracy and required sampling schedule. <i>Diabetologia</i> , 1998, 41, 548-554.	6.3	52
74	Automated Overnight Closed-Loop Glucose Control in Young Children with Type 1 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 419-424.	4.4	52
75	Modeling Day-to-Day Variability of Glucose–Insulin Regulation Over 12-Week Home Use of Closed-Loop Insulin Delivery. <i>IEEE Transactions on Biomedical Engineering</i> , 2017, 64, 1412-1419.	4.2	52
76	Participants' Experiences of, and Views About, Daytime Use of a Day-and-Night Hybrid Closed-Loop System in Real Life Settings: Longitudinal Qualitative Study. <i>Diabetes Technology and Therapeutics</i> , 2019, 21, 119-127.	4.4	52
77	Closed-loop control in insulin pumps for type-1 diabetes mellitus: safety and efficacy. <i>Expert Review of Medical Devices</i> , 2020, 17, 707-720.	2.8	52
78	Young Children Have Higher Variability of Insulin Requirements: Observations During Hybrid Closed-Loop Insulin Delivery. <i>Diabetes Care</i> , 2019, 42, 1344-1347.	8.6	51
79	Fully closed-loop insulin delivery improves glucose control of inpatients with type 2 diabetes receiving hemodialysis. <i>Kidney International</i> , 2019, 96, 593-596.	5.2	51
80	On-line adaptive algorithm with glucose prediction capacity for subcutaneous closed loop control of glucose: evaluation under fasting conditions in patients with Type 1 diabetes. <i>Diabetic Medicine</i> , 2006, 23, 90-93.	2.3	50
81	Artificial pancreas: an emerging approach to treat Type 1 diabetes. <i>Expert Review of Medical Devices</i> , 2009, 6, 401-410.	2.8	50
82	Treatment with Recombinant Human Insulin-Like Growth Factor (rhIGF)-I/rhIGF Binding Protein-3 Complex Improves Metabolic Control in Subjects with Severe Insulin Resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2113-2122.	3.6	50
83	Management of diabetes using adaptive control. <i>International Journal of Adaptive Control and Signal Processing</i> , 2005, 19, 309-325.	4.1	49
84	Stochastic Virtual Population of Subjects With Type 1 Diabetes for the Assessment of Closed-Loop Glucose Controllers. <i>IEEE Transactions on Biomedical Engineering</i> , 2013, 60, 3524-3533.	4.2	49
85	Feasibility of Closed-Loop Insulin Delivery in Type 2 Diabetes: A Randomized Controlled Study. <i>Diabetes Care</i> , 2014, 37, 1198-1203.	8.6	49
86	Variability of Insulin Requirements Over 12 Weeks of Closed-Loop Insulin Delivery in Adults With Type 1 Diabetes. <i>Diabetes Care</i> , 2016, 39, 830-832.	8.6	49
87	Evaluation of a portable ambulatory prototype for automated overnight closed-loop insulin delivery in young people with type 1 diabetes. <i>Pediatric Diabetes</i> , 2012, 13, 449-453.	2.9	48
88	Assessing Performance of Closed-Loop Insulin Delivery Systems by Continuous Glucose Monitoring: Drawbacks and Way Forward. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 4-12.	4.4	48
89	Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol. <i>Diabetes</i> , 2013, 62, 4063-4069.	0.6	47
90	Pharmacokinetics of Insulin Aspart in Pump-Treated Subjects With Type 1 Diabetes: Reproducibility and Effect of Age, Weight, and Duration of Diabetes. <i>Diabetes Care</i> , 2013, 36, e173-e174.	8.6	47

#	ARTICLE	IF	CITATIONS
91	Advances in artificial pancreas systems. Science Translational Medicine, 2019, 11, .	12.4	46
92	Continuous subcutaneous insulin infusion therapy and multiple daily insulin injections in type 1 diabetes mellitus: a comparative overview and future horizons. Expert Opinion on Drug Delivery, 2016, 13, 389-400.	5.0	45
93	Parental Attitudes Towards Overnight Closed-Loop Glucose Control in Children with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2010, 12, 35-39.	4.4	44
94	Experiences of closed-loop insulin delivery among pregnant women with Type 1 diabetes. Diabetic Medicine, 2017, 34, 1461-1469.	2.3	44
95	IGF-I treatment in adults with type 1 diabetes: effects on glucose and protein metabolism in the fasting state and during a hyperinsulinemic-euglycemic amino acid clamp. Diabetes, 2000, 49, 789-796.	0.6	42
96	The Use of Continuous Glucose Monitoring Combined with Computer-Based eMPC Algorithm for Tight Glucose Control in Cardiosurgical ICU. BioMed Research International, 2013, 2013, 1-8.	1.9	42
97	Improving glycemic control in critically ill patients: personalized care to mimic the endocrine pancreas. Critical Care, 2018, 22, 182.	5.8	42
98	Parents's experiences of caring for a young child with type 1 diabetes: a systematic review and synthesis of qualitative evidence. BMC Pediatrics, 2021, 21, 160.	1.7	41
99	Evaluating the Accuracy and Large Inaccuracy of Two Continuous Glucose Monitoring Systems. Diabetes Technology and Therapeutics, 2013, 15, 143-149.	4.4	40
100	A Model-Based Approach to Insulin Adjustment. Lecture Notes in Medical Informatics, 1991, , 239-248.	0.1	40
101	Simulation models for in silico testing of closed-loop glucose controllers in type 1 diabetes. Drug Discovery Today: Disease Models, 2008, 5, 289-298.	1.2	38
102	Effects of prolonged fasting and sustained lipolysis on insulin secretion and insulin sensitivity in normal subjects. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E454-E461.	3.5	38
103	Accuracy of Subcutaneous Continuous Glucose Monitoring in Critically Ill Adults: Improved Sensor Performance with Enhanced Calibrations. Diabetes Technology and Therapeutics, 2014, 16, 97-101.	4.4	38
104	Health professionals' views about who would benefit from using a closed-loop system: a qualitative study. Diabetic Medicine, 2020, 37, 1030-1037.	2.3	38
105	Real-time continuous glucose monitoring in preterm infants (REACT): an international, open-label, randomised controlled trial. The Lancet Child and Adolescent Health, 2021, 5, 265-273.	5.6	38
106	Fully automated closed-loop glucose control compared with standard insulin therapy in adults with type 2 diabetes requiring dialysis: an open-label, randomized crossover trial. Nature Medicine, 2021, 27, 1471-1476.	30.7	38
107	Hybrid closed-loop glucose control compared with sensor augmented pump therapy in older adults with type 1 diabetes: an open-label multicentre, multinational, randomised, crossover study. The Lancet Healthy Longevity, 2022, 3, e135-e142.	4.6	38
108	Suspended insulin infusion during overnight closed-loop glucose control in children and adolescents with Type 1 diabetes. Diabetic Medicine, 2010, 27, 480-484.	2.3	37



#	ARTICLE	IF	CITATIONS
109	Absorption patterns of meals containing complex carbohydrates in type 1 diabetes. <i>Diabetologia</i> , 2013, 56, 1108-1117.	6.3	37
110	Quantitative Measurement of 3-O-Methyl-D-glucose by Gas Chromatography-Mass Spectrometry as a Measure of Glucose Transport In Vivo. , 1996, 31, 961-966.		34
111	Roadmap to the artificial pancreas. <i>Diabetes Research and Clinical Practice</i> , 2006, 74, S178-S182.	2.8	34
112	Technology in the management of type 2 diabetes: Present status and future prospects. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1722-1732.	4.4	34
113	A consultation system for insulin therapy. <i>Computer Methods and Programs in Biomedicine</i> , 1990, 32, 303-310.	4.7	33
114	Five-compartment model of insulin kinetics and its use to investigate action of chloroquine in NIDDM. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 1993, 265, E162-E175.	3.5	33
115	DIAS – the diabetes advisory system: an outline of the system and the evaluation results obtained so far. <i>Computer Methods and Programs in Biomedicine</i> , 1997, 54, 49-58.	4.7	33
116	Accuracy of Continuous Glucose Monitoring During Three Closed-Loop Home Studies Under Free-Living Conditions. <i>Diabetes Technology and Therapeutics</i> , 2015, 17, 801-807.	4.4	33
117	Cambridge hybrid closed-loop algorithm in children and adolescents with type 1 diabetes: a multicentre 6-month randomised controlled trial. <i>The Lancet Digital Health</i> , 2022, 4, e245-e255.	12.3	33
118	Causal probabilistic network modeling – illustration of its role in the management of chronic diseases. <i>IBM Systems Journal</i> , 1992, 31, 635-648.	3.0	32
119	Fitting dynamic models with forcing functions: Application to continuous glucose monitoring in insulin therapy. <i>Statistics in Medicine</i> , 2011, 30, 2234-2250.	1.6	32
120	Pharmacokinetics of Insulin Aspart in Pregnant Women With Type 1 Diabetes: Every Day Is Different. <i>Diabetes Care</i> , 2014, 37, e121-e122.	8.6	32
121	Women's Experiences of Day-and-Night Closed-Loop Insulin Delivery During Type 1 Diabetes Pregnancy. <i>Journal of Diabetes Science and Technology</i> , 2018, 12, 1125-1131.	2.2	32
122	The impact of using a closed-loop system on food choices and eating practices among people with Type 1 diabetes: a qualitative study involving adults, teenagers and parents. <i>Diabetic Medicine</i> , 2019, 36, 753-760.	2.3	32
123	Feasibility of overnight closed-loop therapy in young children with type 1 diabetes aged 3–6 years: comparison between diluted and standard insulin strength. <i>BMJ Open Diabetes Research and Care</i> , 2014, 2, e000040.	2.8	31
124	Impact of liver fat on the differential partitioning of hepatic triacylglycerol into VLDL subclasses on high and low sugar diets. <i>Clinical Science</i> , 2017, 131, 2561-2573.	4.3	31
125	Accuracy of Continuous Glucose Monitoring During Exercise in Type 1 Diabetes Pregnancy. <i>Diabetes Technology and Therapeutics</i> , 2013, 15, 223-229.	4.4	30
126	Glucose Control in the Intensive Care Unit by Use of Continuous Glucose Monitoring: What Level of Measurement Error Is Acceptable?. <i>Clinical Chemistry</i> , 2014, 60, 1500-1509.	3.2	30



#	ARTICLE	IF	CITATIONS
127	Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 1174-1178.	4.4	29
128	Closed-loop for type 1 diabetes – an introduction and appraisal for the generalist. <i>BMC Medicine</i> , 2017, 15, 14.	5.5	29
129	Benefits and Challenges of Current Closed-Loop Technologies in Children and Young People With Type 1 Diabetes. <i>Frontiers in Pediatrics</i> , 2021, 9, 679484.	1.9	29
130	<i>In Silico</i> Testing – Impact on the Progress of the Closed Loop Insulin Infusion for Critically Ill Patients Project. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 417-423.	2.2	28
131	Glucose-responsive insulin delivery for type 1 diabetes: The artificial pancreas story. <i>International Journal of Pharmaceutics</i> , 2018, 544, 309-318.	5.2	28
132	Efficacy and Safety of Glucose Control with Space GlucoseControl in the Medical Intensive Care Unit – An Open Clinical Investigation. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 690-695.	4.4	27
133	Feasibility of automated insulin delivery guided by continuous glucose monitoring in preterm infants. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2020, 105, 279-284.	2.8	27
134	Preliminary experience of the DIAS computer model in providing insulin dose advice to patients with insulin dependent diabetes. <i>Computer Methods and Programs in Biomedicine</i> , 1998, 56, 157-164.	4.7	26
135	Unsupervised home use of an overnight closed-loop system over 3–4 weeks: a pooled analysis of randomized controlled studies in adults and adolescents with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 452-458.	4.4	26
136	Finding the right route for insulin delivery – an overview of implantable pump therapy. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 1103-1111.	5.0	26
137	Bayesian hierarchical approach to estimate insulin sensitivity by minimal model. <i>Clinical Science</i> , 2003, 105, 551-560.	4.3	25
138	Evaluation of nonlinear regression approaches to estimation of insulin sensitivity by the minimal model with reference to Bayesian hierarchical analysis. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2006, 291, E167-E174.	3.5	25
139	Closed-loop insulin delivery: towards improved diabetes care. <i>Discovery Medicine</i> , 2012, 13, 159-70.	0.5	25
140	Interstitial glucose kinetics in subjects with type 1 diabetes under physiologic conditions. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1484-1491.	3.4	24
141	Evaluating Glycemic Control Algorithms by Computer Simulations. <i>Diabetes Technology and Therapeutics</i> , 2011, 13, 713-722.	4.4	24
142	Population and individual minimal modeling of the frequently sampled insulin-modified intravenous glucose tolerance test. <i>Metabolism: Clinical and Experimental</i> , 2004, 53, 1349-1354.	3.4	23
143	Calculating glucose fluxes during meal tolerance test: a new computational approach. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2007, 293, E610-E619.	3.5	23
144	Hospital Glucose Control: Safe and Reliable Glycemic Control Using Enhanced Model Predictive Control Algorithm in Medical Intensive Care Unit Patients. <i>Diabetes Technology and Therapeutics</i> , 2010, 12, 405-412.	4.4	23

#	ARTICLE	IF	CITATIONS
145	Adaptability of Closed Loop During Labor, Delivery, and Postpartum: A Secondary Analysis of Data from Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. <i>Diabetes Technology and Therapeutics</i> , 2018, 20, 501-505.	4.4	23
146	Evaluation of Implementation of a Fully Automated Algorithm (Enhanced Model Predictive Control) in an Interacting Infusion Pump System for Establishment of Tight Glycemic Control in Medical Intensive Care Unit Patients. <i>Journal of Diabetes Science and Technology</i> , 2008, 2, 963-970.	2.2	22
147	Physical Activity Energy Expenditure and Glucose Control in Pregnant Women With Type 1 Diabetes. <i>Diabetes Care</i> , 2013, 36, 1095-1101.	8.6	22
148	The artificial pancreas. <i>Current Opinion in Organ Transplantation</i> , 2020, Publish Ahead of Print, 336-342.	1.6	22
149	CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. , 1998, 19, 39-53.		21
150	Training and Support for Hybrid Closed-Loop Therapy. <i>Journal of Diabetes Science and Technology</i> , 2022, 16, 218-223.	2.2	21
151	Adolescents' and their parents' experiences of using a closed-loop system to manage type 1 diabetes in everyday life: qualitative study. <i>Chronic Illness</i> , 2022, 18, 742-756.	1.5	21
152	Measurement delay associated with the Guardian® RT continuous glucose monitoring system. <i>Diabetic Medicine</i> , 2010, 27, 117-122.	2.3	20
153	Meta-Analysis of Overnight Closed-Loop Randomized Studies in Children and Adults with Type 1 Diabetes: The Cambridge Cohort. <i>Journal of Diabetes Science and Technology</i> , 2011, 5, 1352-1362.	2.2	20
154	Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index. <i>Journal of Diabetes Science and Technology</i> , 2020, 14, 277-283.	2.2	20
155	Use of the DIAS model to predict unrecognised hypoglycaemia in patients with insulin-dependent diabetes. <i>Computer Methods and Programs in Biomedicine</i> , 1996, 50, 241-246.	4.7	19
156	Insulin pump therapy in youth with type 1 diabetes: toward closed-loop systems. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 943-955.	5.0	19
157	Safety, efficacy and glucose turnover of reduced prandial boluses during closed-loop therapy in adolescents with type 1 diabetes: a randomized clinical trial. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 1173-1179.	4.4	19
158	Hypoglycaemia incidence and recovery during home use of hybrid closed-loop insulin delivery in adults with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 2004-2008.	4.4	19
159	Lixisenatide Reduces Chylomicron Triacylglycerol by Increased Clearance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 359-368.	3.6	19
160	Broadening the Debate About Post-trial Access to Medical Interventions: A Qualitative Study of Participant Experiences at the End of a Trial Investigating a Medical Device to Support Type 1 Diabetes Self-Management. <i>AJOB Empirical Bioethics</i> , 2019, 10, 100-112.	1.6	19
161	What Training, Support, and Resourcing Do Health Professionals Need to Support People Using a Closed-Loop System? A Qualitative Interview Study with Health Professionals Involved in the Closed Loop from Onset in Type 1 Diabetes (CLOuD) Trial. <i>Diabetes Technology and Therapeutics</i> , 2020, 22, 468-475.	4.4	19
162	Using a double blind controlled clinical trial to evaluate the function of a Diabetes Advisory System: a feasible approach?. <i>Computer Methods and Programs in Biomedicine</i> , 1998, 56, 165-173.	4.7	18

#	ARTICLE	IF	CITATIONS
163	Associations of Glucose Control with Insulin Sensitivity and Pancreatic $\beta$ -Cell Responsiveness in Newly Presenting Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2002, 87, 198-203.	3.6	18
164	Insulin Administration and Rate of Glucose Appearance in People With Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 2183-2187.	8.6	18
165	Validity of triple- and dual-tracer techniques to estimate glucose appearance. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2012, 302, E1493-E1501.	3.5	18
166	Bringing closed-loop home. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2014, 21, 95-101.	2.3	18
167	Pharmacokinetics of diluted (U20) insulin aspart compared with standard (U100) in children aged 3-6 years with type 1 diabetes during closed-loop insulin delivery: a randomised clinical trial. <i>Diabetologia</i> , 2015, 58, 687-690.	6.3	18
168	Unsupervised overnight closed loop insulin delivery during free living: analysis of randomised cross-over home studies in adults and adolescents with type 1 diabetes. <i>Lancet, The</i> , 2015, 385, S96.	13.7	18
169	Glucose control in intensive care: usability, efficacy and safety of Space GlucoseControl in two medical European intensive care units. <i>BMC Endocrine Disorders</i> , 2014, 14, 62.	2.2	17
170	Glucose Management Indicator (GMI): Insights and Validation Using Guardian 3 and Navigator 2 Sensor Data. <i>Diabetes Care</i> , 2019, 42, e60-e61.	8.6	17
171	Automated Insulin Delivery in Adults. <i>Endocrinology and Metabolism Clinics of North America</i> , 2020, 49, 167-178.	3.2	17
172	Multicentric, Randomized, Controlled Trial to Evaluate Blood Glucose Control by the Model Predictive Control Algorithm Versus Routine Glucose Management Protocols in Intensive Care Unit Patients: Response to Ligtenberg et al.. <i>Diabetes Care</i> , 2006, 29, 1987-1988.	8.6	16
173	Holistic Impact of Closed-Loop Technology on People With Type 1 Diabetes. <i>Journal of Diabetes Science and Technology</i> , 2015, 9, 932-933.	2.2	16
174	Bridging technology and clinical practice: innovating inpatient hyperglycaemia management in non-critical care settings. <i>Diabetic Medicine</i> , 2018, 35, 460-471.	2.3	16
175	Recent advances in closed-loop insulin delivery. <i>Metabolism: Clinical and Experimental</i> , 2022, 127, 154953.	3.4	16
176	AiDAPT: automated insulin delivery amongst pregnant women with type 1 diabetes: a multicentre randomized controlled trial " study protocol. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 282.	2.4	16
177	Gender Differences in VLDL <sub>1</sub> and VLDL <sub>2</sub> Triglyceride Kinetics and Fatty Acid Kinetics in Obese Postmenopausal Women and Obese Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 2475-2481.	3.6	15
178	Glucose control in non-critically ill inpatients with diabetes: towards closed-loop. <i>Diabetes, Obesity and Metabolism</i> , 2014, 16, 500-509.	4.4	15
179	Artificial Pancreas Project at Cambridge 2013. <i>Diabetic Medicine</i> , 2015, 32, 987-992.	2.3	15
180	The importance of prandial insulin bolus timing with hybrid closed-loop systems. <i>Diabetic Medicine</i> , 2019, 36, 1716-1717.	2.3	15

#	ARTICLE	IF	CITATIONS
181	Computer models of albumin and haemoglobin glycation. Computer Methods and Programs in Biomedicine, 1990, 32, 259-263.	4.7	14
182	Analysing the hypoglycaemic counter-regulation: a clinically relevant phenomenon?. Computer Methods and Programs in Biomedicine, 1996, 50, 231-240.	4.7	14
183	DIASâ€œNIDDMâ€œ a model-based decision support system for insulin dose adjustment in insulin-treated subjects with NIDDM. Computer Methods and Programs in Biomedicine, 1998, 56, 175-192.	4.7	14
184	Grading System to Assess Clinical Performance of Closed-Loop Glucose Control. Diabetes Technology and Therapeutics, 2005, 7, 72-82.	4.4	14
185	Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. Diabetic Medicine, 2009, 26, 532-539.	2.3	14
186	Assessing the efficacy, safety and utility of 6-month day-and-night automated closed-loop insulin delivery under free-living conditions compared with insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, multicentre, multinational, single-period, randomised, parallel group study protocol. BMJ Open, 2019, 9, e027856.	1.9	14
187	Who Should Access Closed-Loop Technology? A Qualitative Study of Clinician Attitudes in England. Diabetes Technology and Therapeutics, 2020, 22, 404-410.	4.4	14
188	A qualitative study of clinician attitudes towards closed-loop systems in mainstream diabetes care in England. Diabetic Medicine, 2020, 37, 1023-1029.	2.3	14
189	Duration of Hybrid Closed-Loop Insulin Therapy to Achieve Representative Glycemic Outcomes in Adults With Type 1 Diabetes. Diabetes Care, 2020, 43, e38-e39.	8.6	14
190	Assessing the effect of closed-loop insulin delivery from onset of type 1 diabetes in youth on residual beta-cell function compared to standard insulin therapy (CLOuD study): a randomised parallel study protocol. BMJ Open, 2020, 10, e033500.	1.9	14
191	Associations of Glucose Control with Insulin Sensitivity and Pancreatic Î-Cell Responsiveness in Newly Presenting Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 198-203.	3.6	14
192	Computers in diabetes. Computer Methods and Programs in Biomedicine, 1994, 41, 151-152.	4.7	13
193	Reproducibility and comparability of insulin sensitivity indices measured by stable-label intravenous glucose tolerance test. , 1998, 15, 234-246.		13
194	Mass kinetics of apolipoprotein A-I in interstitial fluid after administration of intravenous apolipoprotein A-I/lecithin discs in humans. Journal of Lipid Research, 2006, 47, 975-981.	4.2	13
195	Intense Exercise in Type 1 Diabetes: Exploring the Role of Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2007, 1, 570-573.	2.2	13
196	Lipohypertrophy and the Artificial Pancreas. Journal of Diabetes Science and Technology, 2014, 8, 915-917.	2.2	13
197	Assessing the effectiveness of a 3-month day-and-night home closed-loop control combined with pump suspend feature compared with sensor-augmented pump therapy in youths and adults with suboptimally controlled type 1 diabetes: a randomised parallel study protocol. BMJ Open, 2017, 7, e016738.	1.9	13
198	Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2718-2722.	4.4	13

#	ARTICLE	IF	CITATIONS
199	Automated Glucose Control in the ICU: Effect of Nutritional Protocol and Measurement Error. , 2006, 2006, 67-70.		12
200	Assessing the effectiveness of 3 months day and night home closed-loop insulin delivery in adults with suboptimally controlled type 1 diabetes: a randomised crossover study protocol. BMJ Open, 2014, 4, e006075-e006075.	1.9	12
201	Mixed-meal tolerance test to assess residual beta-cell secretion: Beyond the area-under-curve of plasma C-peptide concentration. Pediatric Diabetes, 2019, 20, 282-285.	2.9	12
202	User Engagement With the CamAPS FX Hybrid Closed-Loop App According to Age and User Characteristics. Diabetes Care, 2021, 44, e148-e150.	8.6	12
203	Parents' experiences of using remote monitoring technology to manage type 1 diabetes in very young children during a clinical trial: Qualitative study. Diabetic Medicine, 2022, 39, e14828.	2.3	12
204	Lived experience of <scp>CamAPS FX</scp> closed loop system in youth with type 1 diabetes and their parents. Diabetes, Obesity and Metabolism, 2022, 24, 2309-2318.	4.4	12
205	Relation between insulin kinetics and insulin sensitivity in pregnancy. European Journal of Clinical Investigation, 2003, 33, 698-703.	3.4	11
206	A Stepwise Approach toward Closed-Loop Blood Glucose Control for Intensive Care Unit Patients: Results from a Feasibility Study in Type 1 Diabetic Subjects Using Vascular Microdialysis with Infrared Spectrometry and a Model Predictive Control Algorithm. Journal of Diabetes Science and Technology, 2011, 5, 901-905.	2.2	11
207	Estimating postprandial glucose fluxes using hierarchical Bayes modelling. Computer Methods and Programs in Biomedicine, 2012, 108, 102-112.	4.7	11
208	Modelling endogenous insulin concentration in type 2 diabetes during closed-loop insulin delivery. BioMedical Engineering OnLine, 2015, 14, 19.	2.7	11
209	COVID-19 and Diabetes: Could Diabetes Technology Research Help Pave the Way for Remote Healthcare?. Journal of Diabetes Science and Technology, 2020, 14, 735-736.	2.2	11
210	Behavioral Patterns and Associations with Glucose Control During 12-Week Randomized Free-Living Clinical Trial of Day and Night Hybrid Closed-Loop Insulin Delivery in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics, 2017, 19, 433-437.	4.4	11
211	Plasma C-peptide concentration in women with Type-1 diabetes during early and late pregnancy. Diabetic Medicine, 2012, 29, e361-4.	2.3	10
212	Novel Single-Site Device for Conjoined Glucose Sensing and Insulin Infusion: Performance Evaluation in Diabetes Patients During Home-Use. IEEE Transactions on Biomedical Engineering, 2020, 67, 323-332.	4.2	10
213	Assessing the efficacy, safety and utility of closed-loop insulin delivery compared with sensor-augmented pump therapy in very young children with type 1 diabetes (KidsAPO2 study): an open-label, multicentre, multinational, randomised cross-over study protocol. BMJ Open, 2021, 11, e042790.	1.9	10
214	Closed-loop technology: a practical guide. Practical Diabetes, 2021, 38, 33-39.	0.3	10
215	Dynamic updating in DIAS-NIDDM and DIAS causal probabilistic networks. IEEE Transactions on Biomedical Engineering, 1999, 46, 158-168.	4.2	9
216	A novel method for measuring intestinal and hepatic triacylglycerol kinetics. American Journal of Physiology - Endocrinology and Metabolism, 2013, 305, E1041-E1047.	3.5	9

#	ARTICLE	IF	CITATIONS
217	Closing the Loop. Diabetes Technology and Therapeutics, 2016, 18, S-29-S-42.	4.4	9
218	Data Sharing While Using a Closed-Loop System: Qualitative Study of Adolescents' and Parents' Experiences and Views. Diabetes Technology and Therapeutics, 2021, 23, 500-507.	4.4	9
219	Adolescents'™ Experiences of Using a Smartphone Application Hosting a Closed-loop Algorithm to Manage Type 1 Diabetes in Everyday Life: Qualitative Study. Journal of Diabetes Science and Technology, 2021, 15, 1042-1051.	2.2	9
220	Parents'™ experiences of using a hybrid closed-loop system (CamAPS FX) to care for a very young child with type 1 diabetes: Qualitative study. Diabetes Research and Clinical Practice, 2022, 187, 109877.	2.8	9
221	The role of a diabetic advisory system (dias) in the management of insulin-dependent diabetes mellitus. , O, , .		8
222	Risk calculation of type 2 diabetes. Computer Methods and Programs in Biomedicine, 1994, 41, 297-303.	4.7	8
223	The artificial pancreas: making headway. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2007, 24, 56-58.	0.2	8
224	Comment on Doyle et al. Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms. Diabetes Care 2014;37:1191-1197. Diabetes Care, 2014, 37, e226-e227.	8.6	8
225	Closed-Loop Insulin for Glycemic Control in Noncritical Care. New England Journal of Medicine, 2018, 379, 1970-1971.	27.0	8
226	Day-to-day variability of insulin requirements in the inpatient setting: Observations during fully closed-loop insulin delivery. Diabetes, Obesity and Metabolism, 2021, 23, 1978-1982.	4.4	8
227	Constant infusion and bolus injection of stable-label tracer give reproducible and comparable fasting HGO. American Journal of Physiology - Endocrinology and Metabolism, 1997, 273, E192-E201.	3.5	7
228	Evaluating the Performance of a Novel Embedded Closed-loop System. Journal of Diabetes Science and Technology, 2014, 8, 267-272.	2.2	7
229	Rapid model exploration for complex hierarchical data: application to pharmacokinetics of insulin aspart. Statistics in Medicine, 2015, 34, 3144-3158.	1.6	7
230	Faster insulin action is associated with improved glycaemic outcomes during closed-loop insulin delivery and sensor-augmented pump therapy in adults with type 1 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1485-1489.	4.4	7
231	Parents' views about healthcare professionals having real-time remote access to their young child's diabetes data: Qualitative study. Pediatric Diabetes, 2022, 23, 799-808.	2.9	7
232	Factors Associated With Glycemic Control During Free-Living Overnight Closed-Loop Insulin Delivery in Children and Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2015, 9, 1346-1347.	2.2	6
233	Modelling the effect of insulin on the disposal of meal-attributable glucose in type 1 diabetes. Medical and Biological Engineering and Computing, 2017, 55, 271-282.	2.8	6
234	Bolusing frequency and amount impacts glucose control during hybrid closed-loop. Diabetic Medicine, 2018, 35, 347-351.	2.3	6



#	ARTICLE	IF	CITATIONS
235	Lower plasma insulin levels during overnight closed-loop in school children with type 1 diabetes: Potential advantage? A randomized cross-over trial. PLoS ONE, 2019, 14, e0212013.	2.5	6
236	Resistant Starch Production and Glucose Release from Pre-Prepared Chilled Food: The SPUD Project. Nutrition Bulletin, 2021, 46, 52-59.	1.8	6
237	Parenteral Glucose and Glucose Control in the Critically Ill: A Kinetic Appraisal. Journal of Diabetes Science and Technology, 2007, 1, 357-365.	2.2	5
238	Closed-loop in children with type 1 diabetes: Specific challenges. Diabetes Research and Clinical Practice, 2011, 93, S131-S135.	2.8	5
239	Closing the Loop. Diabetes Technology and Therapeutics, 2014, 16, S-23-S-33.	4.4	5
240	Self-Monitoring of Blood Glucose—An Overview. Diabetes Technology and Therapeutics, 2014, 16, S-3-S-10.	4.4	5
241	Pharmacokinetics of insulin lispro in type 2 diabetes during closed-loop insulin delivery. Computer Methods and Programs in Biomedicine, 2014, 117, 298-307.	4.7	5
242	Glucose Turnover After Replacement of Usual Therapy by Insulin in Insulin-naïve Type 2 Diabetes Subjects. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 2225-2232.	3.6	5
243	Estimated HbA 1c and glucose management indicator (GMI): are they the same?. Diabetic Medicine, 2021, 38, e14423.	2.3	5
244	Psychological Well-Being of Parents of Very Young Children With Type 1 Diabetes — Baseline Assessment. Frontiers in Endocrinology, 2021, 12, 721028.	3.5	5
245	Acid-base chemistry of the blood — a general model. Computer Methods and Programs in Biomedicine, 1996, 51, 107-119.	4.7	4
246	Relationship between $\beta$ -cell responsiveness and fasting plasma glucose in Caucasian subjects with newly presenting Type 2 diabetes. Diabetic Medicine, 2001, 18, 797-802.	2.3	4
247	Further Development of Artificial Pancreas: Blocked by Patents?. Journal of Diabetes Science and Technology, 2008, 2, 971-976.	2.2	4
248	Closing the Loop. Diabetes Technology and Therapeutics, 2013, 15, S-29-S-39.	4.4	4
249	Insulin delivery and nocturnal glucose control in children and adolescents with type 1 diabetes. Expert Opinion on Drug Delivery, 2017, 14, 1367-1377.	5.0	4
250	Closed-loop insulin delivery in end-of-life care: a case report. Diabetic Medicine, 2019, 36, 1711-1714.	2.3	4
251	Simulation Models for In-Silico Evaluation of Closed-Loop Insulin Delivery Systems in Type 1 Diabetes. Lecture Notes in Bioengineering, 2014, , 131-149.	0.4	4
252	Identification of insulin receptor systems: Assessing the impact of model selection and measurement error on precision of parameter estimates using monte carlo study. Journal of Theoretical Biology, 1991, 151, 367-383.	1.7	3



#	ARTICLE	IF	CITATIONS
253	Estimating Protein Turnover with a [13N,15C]Leucine Tracer: a Study Using Simulated Data. Journal of Theoretical Biology, 1999, 198, 165-172.	1.7	3
254	Effect of delay on measurement of blood glucose levels in young subjects with type 1 diabetes. Diabetes Research and Clinical Practice, 2009, 86, e31-e33.	2.8	3
255	The Future of the Artificial Pancreas. Diabetes Technology and Therapeutics, 2015, 17, 763-765.	4.4	3
256	Factors Affecting Recruitment of Participants for Studies of Diabetes Technology in Newly Diagnosed Youth with Type 1 Diabetes: A Qualitative Focus Group Study with Parents and Children. Diabetes Technology and Therapeutics, 2016, 18, 568-573.	4.4	3
257	Available at a flash: a new way to check glucose. Lancet, The, 2016, 388, 2213-2214.	13.7	3
258	Rapid Benefits of Structured Optimization and Sensor-Augmented Insulin Pump Therapy in Adults With Type 1 Diabetes. Journal of Diabetes Science and Technology, 2017, 11, 180-181.	2.2	3
259	Sensor Life and Overnight Closed Loop: A Randomized Clinical Trial. Journal of Diabetes Science and Technology, 2017, 11, 513-521.	2.2	3
260	Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. Diabetes Technology and Therapeutics, 2020, 22, 691-696.	4.4	3
261	A Validation Methodology for Testing Decision-Support Systems for Insulin Dosage Adjustment. Lecture Notes in Medical Informatics, 1991, , 382-388.	0.1	3
262	A simulation study to determine optimal insulin priming during glucose clamp studies. Computer Methods and Programs in Biomedicine, 1994, 41, 231-241.	4.7	2
263	Modelling and decision support in physiology and medicine: a methodological framework with Illustration. Mathematical and Computer Modelling of Dynamical Systems, 1998, 4, 73-99.	2.2	2
264	Artificial pancreas: the bridge to a cure for type 1 diabetes. European Diabetes Nursing, 2012, 9, 56-60.	0.2	2
265	A diet low in sugar reduces the production of atherogenic lipoproteins in men with high liver fat. Atherosclerosis, 2015, 241, e46.	0.8	2
266	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2016, 18, S-86-S-100.	4.4	2
267	Effect of nutrition on postprandial glucose control in hospitalized patients with type 2 diabetes receiving fully automated closed-loop insulin therapy. Diabetes, Obesity and Metabolism, 2021, 23, 234-239.	4.4	2
268	214-OR: Cambridge Hybrid Closed-Loop in Children and Adolescents with T1D: A Multicentre Six-Month Randomised Trial. Diabetes, 2021, 70, 214-OR.	0.6	2
269	Optimizing the use of technology to support people with diabetes: research recommendations from Diabetes UK's 2019 diabetes and technology workshop. Diabetic Medicine, 2021, 38, e14647.	2.3	2
270	A Causal Probabilistic Network Model Of Carbohydrate Metabolism For Insulin Therapy Adjustment. , 0, , .		1

#	ARTICLE	IF	CITATIONS
271	A Dynamic Model of Carbon Dioxide Transport in the Blood. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 1997, 30, 57-62.	0.4	1
272	A surrogate measure of whole body leucine transport across the cell membrane. American Journal of Physiology - Endocrinology and Metabolism, 1999, 276, E573-E579.	3.5	1
273	Continuous glucose monitoring in critically ill adults: comparison of two different calibration protocols. Critical Care, 2013, 17, .	5.8	1
274	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2015, 17, S-96-S-108.	4.4	1
275	Closed-loop management of inpatient hyperglycaemia. British Journal of Hospital Medicine (London,) Tj ETQq1 1 0.784314 rgBT /Overdo	0.5	1
276	Does eating a reheated starchy carbohydrate meal improve postprandial glycaemia?. Proceedings of the Nutrition Society, 2020, 79, .	1.0	1
277	Closed-loop insulin delivery system enhances type 1 diabetes glycemic control. Journal of Pediatrics, 2020, 218, 259-262.	1.8	1
278	CODE: a deconvolution program implementing a regularization method of deconvolution constrained to non-negative values. Description and pilot evaluation. Biopharmaceutics and Drug Disposition, 1998, 19, 39-53.	1.9	1
279	A Novel Composite Glucose Index (COGI) for Evaluating Closed-Loop Performance in Type 1 Diabetes. Diabetes, 2018, 67, .	0.6	1
280	Continuous glucose monitoring in extremely preterm infants in intensive care: the REACT RCT and pilot study of "closed-loop"™ technology. Efficacy and Mechanism Evaluation, 2021, 8, 1-142.	0.7	1
281	Strategies For Insulin Dosage Adjustment Using Model-based Blood Glucose Prediction. , 0, , .		0
282	Computer simulation in clinical practice. International Journal of Medical Informatics, 1997, 45, 129-130.	3.3	0
283	Insulin sensitivity of glucose transport and glucose disposal during IVGTT. Diabetes Research and Clinical Practice, 2000, 50, 163.	2.8	0
284	Modeling interstitial glucose kinetics in subjects with type I diabetes during physiological conditions. , 0, , .		0
285	Evaluation of cold two compartment minimal model in type 2 diabetes. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 445-450.	0.4	0
286	Reduced sampling protocols with Bayesian hierarchical analysis during minimal model of IVGTT. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2003, 36, 421-425.	0.4	0
287	TIME-VARIANT INSULIN SENSITIVITY IN CRITICALLY ILL SUBJECTS. IFAC Postprint Volumes IPPV / International Federation of Automatic Control, 2006, 39, 458-462.	0.4	0
288	Technological advances in pregnancy complicated by type 1 diabetes. Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide, 2011, 28, 104.	0.2	0

#	ARTICLE	IF	CITATIONS
289	Response to Mitre et al.: “Analysis of Continuous Glucose Monitoring Data to Assess Outpatient Closed-Loop Studies: Considerations for Different Sensors” Diabetes Technology and Therapeutics, 2014, 16, 328-329.	4.4	0
290	Diabetes Technology and Therapy in the Pediatric Age Group. Diabetes Technology and Therapeutics, 2014, 16, S-100-S-109.	4.4	0
291	Prandial Hypertriglyceridemia in Metabolic Syndrome Is Due to an Overproduction of Both Chylomicron and VLDL Triacylglycerol. Diabetes 2013;62:4063-4069. Diabetes, 2014, 63, 815-815.	0.6	0
292	Closing the Loop. Diabetes Technology and Therapeutics, 2015, 17, S-27-S-38.	4.4	0
293	Closed-Loop Insulin Delivery During Pregnancy in Women With Type 1 Diabetes. Obstetrical and Gynecological Survey, 2016, 71, 699-701.	0.4	0
294	The use of closed loop in outpatient/home studies. Diabetes Research and Clinical Practice, 2016, 120, S21.	2.8	0
295	Role of Dual-Hormone Closed-Loop Delivery System in the Future. Diabetes Technology and Therapeutics, 2016, 18, 452-454.	4.4	0
296	Cover Image, Volume 19, Issue 10. Diabetes, Obesity and Metabolism, 2017, 19, i-i.	4.4	0
297	Sensor mightier than pump—the jury is still out. Lancet Diabetes and Endocrinology, the, 2017, 5, 672-673.	11.4	0
298	Glucose Monitoring and Insulin Pump Therapy in the Management of Children and Adolescents with Type 1 Diabetes. , 2017, , 163-172.		0
299	Effect of fully automated closed-loop insulin delivery using faster aspart versus standard aspart on gluco-regulatory hormones in type 2 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 228-233.	4.4	0
300	Progress with Closed-loop Systems in Type 1 Diabetes. European Endocrinology, 2010, 6, 31.	1.5	0
301	Consultation System for Insulin Dosage Adjustment. Lecture Notes in Medical Informatics, 1991, , 1044-1044.	0.1	0
302	Ten Years of Computer Support in a Metabolic Intensive Care Unit. Lecture Notes in Medical Informatics, 1991, , 930-933.	0.1	0
303	Fully Closed-Loop Glucose Control in Noncritical Care Settings—a Randomised, Controlled Two-Centre Study. Diabetes, 2018, 67, 350-OR.	0.6	0
304	Looking Beyond HbA1c—Evaluating Glycaemic Control during Closed-Loop Use in Type 1 Diabetes. Diabetes, 2018, 67, .	0.6	0
305	Adaptability of Closed-Loop during Labor, Delivery, and Postpartum—a Secondary Analysis of Data From Two Randomized Crossover Trials in Type 1 Diabetes Pregnancy. Diabetes, 2018, 67, .	0.6	0
306	1039-P: Hybrid Closed-Loop in Adults with Type 1 Diabetes: Impact of Baseline A1c on Glucose Outcomes and Insulin Delivery. Diabetes, 2019, 68, 1039-P.	0.6	0

#	ARTICLE	IF	CITATIONS
307	1047-P: Can Closed-Loop Overcome High Day-to-Day Variability of Insulin Needs in Inpatients on General Wards?. Diabetes, 2019, 68, .	0.6	0
308	1046-P: Day-to-Day Variability of Insulin Requirements in Inpatients on General Wards. Diabetes, 2019, 68, .	0.6	0
309	79-OR: Fully Closed-Loop Using Faster vs. Standard Aspart in Type 2 Diabetes (T2D): A Double-Blind Randomised Crossover Trial. Diabetes, 2019, 68, .	0.6	0
310	115-LB: Optimal Sampling Duration of Hybrid Closed-Loop Therapy to Determine Long-Term Glycemic Control in Adults with Type 1 Diabetes. Diabetes, 2019, 68, .	0.6	0
311	Closed-loop management of inpatient hyperglycemia. Aging, 2019, 11, 5292-5293.	3.1	0
312	Can exenatide flatten the post-prandial glucose curve in type 1 diabetes?. Annals of Translational Medicine, 2020, 8, 1535.	1.7	0